MTOR and breast neoplasm: Signatures from both Saal et al. (PTEN loss in human breast tumors) and Connectivity Map (PI3K/mTOR inhibitor treatment in vitro) showed similar patterns: the basal-like subtype had the highest PI3K pathway activity and luminal A had the lowest pathway activity [32,34].